Compare ACCL & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACCL | IXHL |
|---|---|---|
| Founded | 2009 | 2001 |
| Country | Hong Kong | Australia |
| Employees | N/A | N/A |
| Industry | Professional Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.8M | 49.1M |
| IPO Year | 2025 | N/A |
| Metric | ACCL | IXHL |
|---|---|---|
| Price | $3.10 | $0.41 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 82.0K | ★ 12.2M |
| Earning Date | 02-20-2026 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 2.91 | N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $4,888,824.00 | $12,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $35.11 | ★ N/A |
| Revenue Growth | ★ 11.91 | N/A |
| 52 Week Low | $2.10 | $0.08 |
| 52 Week High | $5.00 | $2.25 |
| Indicator | ACCL | IXHL |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 52.15 |
| Support Level | N/A | $0.35 |
| Resistance Level | N/A | $0.47 |
| Average True Range (ATR) | 0.00 | 0.03 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 0.00 | 48.04 |
Acco Group Holdings Ltd is a holding company. Through its Operating Subsidiaries, it is a multi-disciplinary, IT-driven corporate service provider with a presence in Hong Kong and Singapore. Under the Accolade brand, it specializes in offering corporate secretarial services and accounting services in Hong Kong, as well as intellectual properties (IP) registration services in Singapore. Leveraging developed IT solutions, It provides comprehensive, reliable and professional support to its clients, enabling them to focus on their core business activities while it manages and handles their corporate compliance needs. Its clientele ranges from individual clients, small and medium-sized enterprises to multinational corporations, reflecting its ability to cater to diverse business needs.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.